Cardiac contractility modulation, or CCM, is a device-based therapy for heart failure that delivers precisely timed electrical signals to the heart muscle during each heartbeat. Unlike a pacemaker or defibrillator, CCM doesn’t control the heart’s rhythm. Instead, it strengthens the force of each contraction by changing how heart muscle cells handle calcium, the mineral that drives every heartbeat. The therapy is designed for people with moderate heart failure who are still experiencing symptoms despite being on optimal medication.
How CCM Works Inside the Heart
During a normal heartbeat, an electrical signal triggers heart muscle cells to release calcium, which causes the muscle to contract. In heart failure, this calcium cycling becomes impaired: cells don’t release enough calcium, don’t reabsorb it efficiently, and the molecular machinery that powers contraction starts to degrade. Over time, the heart actually reverts to using a “fetal gene program,” producing less effective versions of the proteins it needs to pump blood.
CCM sends relatively high-voltage electrical pulses to the heart during the absolute refractory period, a brief window right after each heartbeat when the heart muscle can’t contract again. Because the signal arrives during this window, it doesn’t trigger an extra beat. What it does instead is change the behavior of the muscle cells at a molecular level. Within months, CCM normalizes the way cells store and release calcium, restores the production of adult versions of key contractile proteins, and improves the function of structural proteins that give heart muscle its elasticity. These changes happen in both the cells directly stimulated by the device and in surrounding tissue, suggesting a broader signaling effect.
The practical result is that the heart pumps more forcefully with each beat. After about three months of therapy, imaging studies show that the heart begins to reverse remodel, meaning it gradually returns toward a more normal size and shape rather than continuing to enlarge.
Who Qualifies for CCM
The FDA authorized CCM specifically for people with NYHA Class III heart failure, a stage where everyday activities like walking up stairs or carrying groceries cause significant fatigue or shortness of breath. To qualify, you need to meet several criteria:
- Ejection fraction between 25% and 45%. This is the percentage of blood your heart pumps out with each beat. A healthy heart ejects about 55% to 70%.
- At least 3 months on optimized medication. CCM is not a first-line treatment. You need to have been on guideline-directed medical therapy, with doses adjusted as high as you can tolerate, and still have persistent symptoms.
- Normal sinus rhythm. Your heart needs to be beating in its natural rhythm pattern, not in atrial fibrillation.
- Narrow QRS complex, typically 130 milliseconds or less. This measurement on an EKG reflects how electrical signals spread through the ventricles.
- Not a candidate for cardiac resynchronization therapy (CRT). CCM fills a gap for patients who don’t qualify for CRT.
That last point is important because it defines who CCM is really for. CRT works by coordinating the timing of the left and right ventricles in patients whose electrical signals are delayed (wide QRS complex). CCM targets a completely different problem: weak contraction strength in patients whose electrical timing is already normal.
How CCM Differs From CRT
CRT and CCM are both implantable devices for heart failure, but they solve different problems for different patients. CRT corrects a timing issue. If the two sides of your heart are contracting out of sync, CRT paces them together so they pump more efficiently. This only works if your QRS duration is wide, typically above 130 to 150 milliseconds, indicating a conduction delay.
CCM, by contrast, doesn’t change when your heart beats. It changes how strongly it beats. Your QRS stays the same (around 110 milliseconds on average in studies), because the device isn’t pacing the heart at all. A comparison study found that after 12 months, CCM and CRT patients experienced comparable improvements in functional status and reverse remodeling. Notably, the CCM patients in that study started out sicker, with lower ejection fractions (about 24% vs. 26%) and worse symptom scores, yet still achieved similar gains.
Clinical Evidence
The pivotal trial behind CCM’s FDA authorization was the FIX-HF-5C study, a randomized controlled trial that compared CCM plus standard medical therapy against medical therapy alone. Patients receiving CCM showed a statistically significant improvement in peak oxygen consumption, gaining 0.84 ml O2/kg/min more than the control group. That number may sound modest, but in advanced heart failure, where exercise capacity is severely limited, it represents a meaningful change in what patients can physically do.
Quality of life improved significantly as well. Patients scored better on the Minnesota Living With Heart Failure questionnaire, a standard measure that captures how much heart failure interferes with daily life. They also walked farther on the 6-minute walk test and showed improvements in NYHA functional class, meaning their symptoms during routine activities became noticeably less limiting.
The Device and Implantation
The CCM system, marketed as the Optimizer, consists of a small pulse generator (roughly the size of a pacemaker) implanted under the skin below the collarbone, along with three thin wires called leads. One lead goes into the right atrial appendage to sense the heart’s natural rhythm. Two leads are placed in the right ventricle, positioned along the septum (the wall between the two lower chambers) about 2 centimeters apart. These ventricular leads deliver the CCM signal.
The implantation procedure is similar to receiving a pacemaker. It’s performed through a small incision near the collarbone, with leads threaded through a vein into the heart under imaging guidance. Most patients go home the same day or the next.
Living With a CCM Device
One difference between CCM and most other cardiac implants is the battery. The Optimizer uses a rechargeable lithium-ion battery rather than a fixed-life battery that requires surgical replacement every few years. You charge it yourself about once a week using a handheld charger held over the device through the skin. The manufacturer estimates the battery lasts approximately 15 years before the device needs replacement.
The device is programmed by your cardiologist using a dedicated programmer during office visits. CCM signals are typically delivered for several hours per day in scheduled windows, and the device continuously senses your heart rhythm to ensure signals are only delivered during normal sinus beats. If it detects an irregular rhythm, it withholds the signal.
Because CCM doesn’t replace a defibrillator or pacemaker, many patients have a CCM device alongside an existing implantable cardioverter-defibrillator. The two devices can coexist, though lead placement requires careful coordination during implantation.
What Improvement Looks Like
CCM is not a cure for heart failure, and the improvements it delivers are gradual. Most of the molecular changes in heart muscle take about three months to become measurable, and reverse remodeling of the heart’s structure continues beyond that. Patients generally notice that they can do more before becoming winded, that daily activities feel less exhausting, and that their overall quality of life improves. The therapy works alongside your existing medications, not as a replacement for them.